Clinical Program
Clinical Program
Racura is progressing a robust pipeline of clinical activities for RC220, a proprietary formulation of (E,E)-bisantrene designed to enable peripheral and central intravenous administration, in three indications.
Bisantrene has an extensive clinical history in treating AML and was approved in France for the treatment of relapsed or refractory (R/R) AML in 1988.
Racura Oncology is undertaking a Phase 3 program of RC220 in R/R AML with first patient expected to be treated in H2 2026.
Racura Oncology is undertaking a Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC). This trial named HARNESS-1 utilises ctDNA to provide NSCLC patients additional treatment with RC220 with the aim of preventing or delaying osimertinib treatment failure.
Bisantrene has proven clinical efficacy in a range of solid tumour cancers with lower heart toxicity than other widely used chemotherapies.
Bisantrene was explored as a new breast cancer treatment in seven Phase 2 and 3 clinical trials in the 1980s. In the large Phase 3 trial, bisantrene showed equivalent patient survival efficacy as doxorubicin, a current standard of care chemotherapeutic, but with significantly lower rates of serious damage to the heart (4% bisantrene verses 23% doxorubicin). Bisantrene also showed much lower rates of hair loss (alopecia) than doxorubicin.
Racura Oncology have identified in preclinical models that the combination of RC220 and doxorubicin can better treat cancers while also protecting the heart from the permanent damage caused by doxorubicin chemotherapy.
Racura is undertaking a Phase 1 clinical trial of RC220 in combination with doxorubicin in patients with advanced solid tumours, named the CPACS trial . For further information about the CPACS trial please contact us at trials@racuraoncology.com.
